1.
|
|
2.
|
6 p, 1.1 MB |
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study
/
Nahi, Hareth (Karolinska Institute. Department of Medicine) ;
Usmani, Saad Z. (Memorial Sloan Kettering Cancer Center) ;
Mateos, M. V (University Hospital of Salamanca) ;
van de Donk, Niels W C J (Department of Hematology. Vrije Universiteit Amsterdam) ;
Oriol, Albert. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Plesner, Torben (Vejle Hospital and University of Southern Denmark) ;
Bandyopadhyay, Nibedita (Janssen Research & Development. LLC) ;
Hellemans, Peter (Janssen Research & Development) ;
Tromp, Brenda (Janssen Research & Development. LLC) ;
Nnane, Ivo (Janssen Research & Development. LLC) ;
Zemlickis, Donna (Janssen Research & Development. LLC) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai) ;
Moreau, Philippe (Hematology Department. University Hospital Hôtel-Dieu)
2023 - 10.1080/10428194.2022.2148221
Leukemia and Lymphoma, Vol. 64 Núm. 2 (2023) , p. 468-472
|
|
3.
|
13 p, 471.4 KB |
Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial
/
Dimopoulos, Meletios (National and Kapodistrian University of Athens) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nahi, Hareth (Department of Medicine. Karolinska University) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Bahlis, Nizar J. (University of Calgary) ;
Usmani, S. Z (Memorial Sloan Kettering Cancer Center) ;
Rabin, Neil (Department of Haematology. University College London Hospitals NHS Trust) ;
Orlowski, Robert Z. (Department of Lymphoma and Myeloma. The University of Texas) ;
Suzuki, Kenshi (Department of Hematology. Japanese Red Cross Medical Center) ;
Plesner, Torben (University of Southern Denmark) ;
Yoon, Sung Soo (Department of Internal Medicine. Seoul National University) ;
Ben Yehuda, Dina (Hematology Department. Hebrew University) ;
Richardson, Paul G. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Goldschmidt, Hartmut (University Hospital Heidelberg) ;
Reece, Donna (Department of Medical Oncology and Hematology. Princess Margaret Cancer Centre) ;
Ahmadi, Tahamtan (Genmab US (Estats Units d'Amèrica)) ;
Qin, Xiang (Janssen Research & Development (Xina)) ;
Garvin Mayo, Wendy (Janssen Research & Development (Estats Units d'Amèrica)) ;
Gai, Xue (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carey, Jodi (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carson, Robin (Janssen Research & Development (Estats Units d'Amèrica)) ;
Moreau, Philippe (Hematology Department. University Hospital Hôtel-Dieu)
PURPOSEWith the initial analysis of POLLUX at a median follow-up of 13. 5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2023 - 10.1200/JCO.22.00940
Journal of Clinical Oncology, Vol. 41 Núm. 8 (october 2023) , p. 1590-1599
|
|
4.
|
8 p, 775.2 KB |
Bias in dissemination of clinical research findings : Structured OPEN framework of what, who and why, based on literature review and expert consensus
/
Bassler, Dirk (University Hospital Zurich) ;
Mueller, Katharina F. (University Children's Hospital Tuebingen) ;
Briel, Matthias (University Hospital Basel) ;
Kleijnen, Jos (Maastricht University) ;
Marusic, Ana (University of Split) ;
Wager, Elizabeth (Sideview) ;
Antes, Gerd (University of Freiburg) ;
Von Elm, Erik (University Hospital Lausanne) ;
Altman, Douglas G. (University of Oxford) ;
Meerpohl, Joerg J. (University of Freiburg) ;
Bertelè, Vittorio (IRCCS-Istituto di Ricerche Farmacologiche Mario Negri) ;
Bonfill, X. (Xavier) (Institut d'Investigació Biomèdica Sant Pau) ;
Bouesseau, Marie-Charlotte (WHO) ;
Boutron, Isabelle (Paris Descartes University) ;
Gallus, Silvano (IRCCS-Istituto di Ricerche Farmacologiche Mario Negri) ;
Garattini, Silvio (IRCCS-Istituto di Ricerche Farmacologiche Mario Negri) ;
Ghersi, Davina (University of Sydney) ;
Karam, Ghassan (World Health Organization) ;
Kulig, Michael (Federal Joint Committee) ;
La Vecchia, Carlo (University of Milan) ;
Littmann, Jasper (Hannover Medical Scholl) ;
Malički, Mario (University of Split) ;
Murisic, Bojana (IRCCS-Istituto di Ricerche Farmacologiche Mario Negri) ;
Nolting, Alexandra (Federal Joint Committee) ;
Pardo-Hernandez, Hector (Institut d'Investigació Biomèdica Sant Pau) ;
Perleth, Matthias (Federal Joint Committee) ;
Ravaud, Philippe (Paris Descartes University) ;
Reis, Andreas (World Health Organization) ;
Schell, Lisa (University of Freiburg) ;
Schmucker, Christine (University of Freiburg) ;
Schwarzer, Guido (University of Freiburg) ;
Strech, Daniel (Hannover Medical Scholl) ;
Trinquart, Ludovic (Paris Descartes University) ;
Urrútia, Gerard (Institut d'Investigació Biomèdica Sant Pau) ;
Wolff, Robert (Kleijnen Systematic Reviews Ltd) ;
Universitat Autònoma de Barcelona
The aim of this study is to review highly cited articles that focus on non-publication of studies, and to develop a consistent and comprehensive approach to defining (non-) dissemination of research findings. [...]
2016 - 10.1136/bmjopen-2015-010024
BMJ open, Vol. 6 Núm. 1 (2016) , p. e010024
|
|
5.
|
11 p, 830.0 KB |
Rationale and study design for an individualised perioperative open-lung ventilatory strategy with a high versus conventional inspiratory oxygen fraction (iPROVE-O2) and its effects on surgical site infection : Study protocol for a randomised controlled trial
/
Ferrando, Carlos (Hospital Clínico Universitario de València de València) ;
Soro, Marina (Hospital Clínico Universitario de València) ;
Unzueta, Carmen (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Canet, Jaume (Hospital Germans Tries i Pujol) ;
Tusman, Gerardo (Hospital Privado de Comunidad Mar de Plata) ;
Suarez-Sipmann, Fernando (Uppsala University Hospital) ;
Librero, Julian (Navarrabiomed Fundación Miguel Servet) ;
Peiró, Salvador (Centro Superior de Investigación en Salud Pública (CSISP FISABIO)) ;
Pozo, Natividad (Hospital Clínico Universitario de València) ;
Delgado, Carlos (Hospital Clínico Universitario de València) ;
Ibáñez, Maite (Hospital de Villajoyosa) ;
Aldecoa, Cesar (Hospital de Villajoyosa) ;
Garutti, Ignacio (Hospital General de Ciudad Real Gregorio Marañon) ;
Pestaña, David (Hospital Universitario Ramón y Cajal (Madrid)) ;
Rodríguez, Aurelio (Hospital Dr. Negrín Gran Canaria) ;
García Del Valle, Santiago (Hospital Fundación of Alcorcón) ;
Diaz-Cambronero, Oscar (Hospital la Fe) ;
Balust, Jaume (Hospital Clínic i Provincial de Barcelona) ;
Redondo, Francisco Javier (Hospital General de Ciudad Real) ;
De La Matta, Manuel (Hospital Vírgen Del Rocio) ;
Gallego, Lucía (Hospital Universitario Miguel Servet (Saragossa)) ;
Granell, Manuel (Hospital General de Ciudad Real) ;
Martínez, Pascual (Hospital de Albacete) ;
Pérez, Ana (Hospital General Universitario de Elche) ;
Leal, Sonsoles (Hospital Povisa) ;
Alday, Kike (Hospital la Princesa) ;
García, Pablo (Hospital 12 de Octubre (Madrid)) ;
Monedero, Pablo (Clínica Universidad de Navarra) ;
Gonzalez, Rafael (Hospital Universitario de León) ;
Mazzinari, Guido (Hospital de Manises (València)) ;
Aguilar, Gerardo (Hospital Clínico Universitario de València) ;
Villar, Jesús (St. Michael's Hospital) ;
Belda, Francisco Javier (Hospital Clínico Universitario de València) ;
Argilaga Nogués, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Azparren Cabezón, Gonzalo (Institut d'Investigació Biomèdica Sant Pau) ;
Felipe, Maria Mar (Institut d'Investigació Biomèdica Sant Pau) ;
India, Inmaculada (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Surgical site infection (SSI) is a serious postoperative complication that increases morbidity and healthcare costs. SSIs tend to increase as the partial pressure of tissue oxygen decreases: previous trials have focused on trying to reduce them by comparing high versus conventional inspiratory oxygen fractions (FIO 2) in the perioperative period but did not use a protocolised ventilatory strategy. [...]
2017 - 10.1136/bmjopen-2017-016765
BMJ open, Vol. 7 Núm. 7 (january 2017) , p. 16765
|
|
6.
|
5 p, 495.6 KB |
Multiband printed monopole antennas loaded with Open Complementary Aplit Ring Resonators (OCSRRs) for PANs and WLANs
/
Herraiz-Martínez, Francisco Javier (Universitat Autònoma de Barcelona. Departament d'Enginyeria Electrònica) ;
Zamora González, Gerard (Universitat Autònoma de Barcelona. Departament d'Enginyeria Electrònica) ;
Paredes, Ferran (Universitat Autònoma de Barcelona. Departament d'Enginyeria Electrònica) ;
Martín, Ferran (Martín Antolín) (Universitat Autònoma de Barcelona. Departament d'Enginyeria Electrònica) ;
Bonache Albacete, Jordi (Universitat Autònoma de Barcelona. Departament d'Enginyeria Electrònica)
Multiband printed monopole antennas loaded with open complementary split-ring resonators (OCSRRs) are presented. The OCSRRs, modeled as parallel LC resonant tanks, act as high-impedance elements at their resonance frequencies, and different effective λ/4 sections can be achieved in the monopole by placing them at proper locations. [...]
2011 - 10.1109/LAWP.2011.2181309
IEEE antennas and wireless propagation letters, Vol. 10 (Dec. 2011) , p. 1528-1531
|
|
7.
|
9 p, 613.6 KB |
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia : Primary analysis of the randomized, open-label mable study
/
Michallet, Anne-Sophie (CLCC Centre Léon Bérard) ;
Aktan, Melih (Istanbul University) ;
Hiddemann, Wolfgang (Ludwig- Maximilians University of Munich) ;
Ilhan, Osman (Ankara University School of Medicine) ;
Johansson, Peter (Uddevalla Hospital) ;
Laribi, Kamel (Centre Hospitalier du Mans) ;
Meddeb, Balkis (Aziza Othmana University Hospital) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Raposo, Joäo (Hospital de Santa Maria) ;
Schuh, Anna (Oxford University Hospitals) ;
Ünal, Ali (Erciyes University Medical School) ;
Widenius, Tom (Peijas Hospital) ;
Bernhardt, Alf (F. Hoffmann-La Roche Ltd) ;
Kellershohn, Kerstin (Roche Pharma AG) ;
Messeri, Dimitri (F. Hoffmann-La Roche Ltd) ;
Osborne, Stuart (F. Hoffmann-La Roche Ltd) ;
Leblond, Véronique (UPMC University) ;
Universitat Autònoma de Barcelona
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. [...]
2018 - 10.3324/haematol.2017.170480
Haematologica, Vol. 103 Núm. 4 (23 2018) , p. 698-706
|
|
8.
|
7 p, 715.4 KB |
Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting : Protocol for a phase IV, single-arm, open-label trial
/
Gil, Emilio (Ferrer Internacional. S.A.) ;
Garcia-Alonso, Fernando (Ferrer Internacional. S.A.) ;
Boldeanu, Anca (Ferrer Internacional. S.A.) ;
Baleeiro Teixeira, Thaïs (Ferrer Internacional. S.A.) ;
Tordera, Vicente (Hospital Lluís Alcanyis) ;
Viciedo, Ramón Palmer (Hospital Provincial de Castelló) ;
Salgado Serrano, Dr Purificación (Hospital del Mar (Barcelona, Catalunya)) ;
Domingo Ribas, Jordi (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Corripio, Iluminada (Institut d'Investigació Biomèdica Sant Pau) ;
Montes, José Manuel (Hospital Universitario Ramón y Cajal (Madrid)) ;
Lauffer, Javier Correas (Hospital Univ de Henares) ;
Murugarrem, Salvador Ruiz (Hospital Príncipe de Asturias) ;
García, Santiago Ovejero (Hospital Universitario Fundación Jiménez Díaz) ;
Mora, Fenando (Hospital Universitario Infanta Leonor) ;
López, Presentación Ataz (Complejo Hospitalario Torrecárdenas (Almeria)) ;
Navas, Andrés Fontalba (Hospital la Inmaculada) ;
Pinto, Ana Mª González (Hospital Santiago Apóstol) ;
Martínez, Ricardo (Hospital Virgen Del Mirón) ;
Castrillo, César García (Complejo Hospitalario de Jaen) ;
Toledo, Francisco (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Vieta, Eduard (Hospital Clínic i Provincial de Barcelona) ;
González, Emilio (Hermanas Hospitalarias Sociosanitario Palencia) ;
Franco, Manuel (Complejo Asistencial Zamora) ;
Drasovean, Nicolae Virgil (Spitalul de Psihiatrie 'Elisabeta Doamna' Galati) ;
Dahl, Nils Hâvard (Helse Nord-Trøndelag HV Sykehuset Levanger) ;
Skagen, Bo (Spesialistesenteret På Straume-Helsesenteret) ;
Zilles, David (Klinik Für Psychiatrie und Psychotherapie der Universitätsmedizin Göttingen) ;
Zwanzger, Peter (Allgemeinpsychiatrie und Psychosomatik) ;
Juckel, Georg (LWL-Universitätsklinikum Bochum der Ruhr-Universität Bochum) ;
Kahl, Kai G. (Medizinische Hochschule Hannover) ;
Messer, Thomas (Fachklinik Für Psychiatrie) ;
Kasper, Siegfried (Medizinische Universität Wien Universitätsklinik Für Psychiatrie und Psychotherapie) ;
Universitat Autònoma de Barcelona
There is a need for fast-acting, non-injection antiagitation treatments that are well tolerated and can be used outside of healthcare facilities. In phase II/III trials, an inhaled formulation of loxapine (ADASUVE®), a well-established, first-generation antipsychotic agent, provided rapid control of mild to moderate agitation in the hospital setting. [...]
2018 - 10.1136/bmjopen-2017-020242
BMJ open, Vol. 8 Núm. 10 (january 2018) , p. e020242
|
|
9.
|
9 p, 544.7 KB |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI) : A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
/
Podzamczer, Daniel (Hospital Universitari de Bellvitge) ;
Micán, R. (Hospital Universitario La Paz (Madrid)) ;
Tiraboschi, Juan Manuel (Hospital Universitari de Bellvitge) ;
Portilla, J. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Llibre, Josep M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ribera, E. (Hospital Universitari Vall d'Hebron) ;
Vivancos, M.J. (Hospital Universitario Ramón y Cajal) ;
Morano, L. (Hospital Álvaro Cunqueiro (Vigo)) ;
Masiá, M. (Hospital General Universitario de Elche) ;
Gómez, C. (Hospital Universitario Virgen de la Victoria-IBIMA) ;
Fanjul, F. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Payeras, A. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Inciarte, Alexy (Hospital Clínic i Provincial de Barcelona) ;
Estrada, V. (Hospital Clínico San Carlos-IdiSSC) ;
Rivero, A. (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Castro, A. (Complejo Hospitalario Universitario) ;
Bernal, Enrique (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Vinuesa, D. (Hospital Universitario San Cecilio (Granada)) ;
Knobel Freud, Hernando (Hospital del Mar (Barcelona, Catalunya)) ;
Troya, J. (Hospital Universitario Infanta Leonor) ;
MacÍas, J. (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ;
Montero, M. (Hospital Universitari i Politècnic la Fe) ;
Sanz, J. (Hospital Universitario de la Princesa (Madrid)) ;
Navarro-Alcaraz, Antonio (Hospital Universitari de Bellvitge) ;
Caicedo, A. (Ris Red de Investigación en Sida) ;
Fernández, G. (Hospital Universitari de Bellvitge) ;
Martínez, Esteban (Hospital Clínic i Provincial de Barcelona) ;
Moreno, S. (Hospital Universitario Ramón y Cajal) ;
Universitat Autònoma de Barcelona
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C/F/TAF and combination therapy based on integrase inhibitors in antiretroviral-naive patients are lacking. [...]
2022 - 10.1093/ofid/ofab595
Open Forum Infectious Diseases, Vol. 9 Núm. 3 (january 2022) , p. ofab595
|
|
10.
|
8 p, 447.7 KB |
Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational : Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure
/
Blanco-García, F.J (INIBIC-Complejo Hospitalario Universitario A Coruña) ;
Rubio-Romero, E. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sanmartí, Raimon (Hospital Clínic i Provincial de Barcelona) ;
Díaz Torne, César (Institut d'Investigació Biomèdica Sant Pau) ;
Talavera, P. (UCB Pharma) ;
Dunkel, J. (UCB Pharma) ;
Naredo, E. (Hospital Fundación Jiménez Díaz) ;
Universitat Autònoma de Barcelona
To assess the effectiveness and safety of certolizumab pegol (CZP) in Spanish patients with RA. SONAR (NCT01526434), a 12-week, open-label, prospective, observational, multicenter study. Patients with active RA for ≥3 months, according to ACR criteria, were treated with CZP (400 mg at Weeks 0, 2 and 4, then 200 mg every 2 weeks). [...]
2020 - 10.1016/j.reuma.2018.07.009
Reumatologia Clinica, Vol. 16 Núm. 5 (septiembre 2020) , p. 345-352
|
|